NEO — NeoGenomics, Inc.

Is NEO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Neutral As of August 19, 2026

NeoGenomics, Inc. (NEO) currently reads Neutral on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $15.90. The rating moved from Overbought to Neutral on August 19, 2026.

AI analysis

NeoGenomics is well positioned in oncology diagnostics with a diversified test menu, recurring volume base, and scale advantages that support margin improvement as volumes recover and new assays commercialize. Near-term catalysts include continued demand for cancer screening and readthrough benefits to CRO/biologics suppliers from positive oncology biologics data, which can drive higher pharma testing and partnerships. However, payer-driven pricing pressure, competition from other diagnostics and liquid-biopsy entrants, and execution risks around capacity and integration temper near-term upside. Financial health reflects historically recurring revenue from clinical and pharma channels, but margins and growth will depend on reimbursement dynamics, volume trends, and successful commercialization of new tests. If screening adoption and pharma services accelerate, upside to revenue and margin is plausible; conversely, adverse reimbursement actions or material volume softness would meaningfully constrain performance.

Key factors

  • Strong market position in oncology diagnostics and molecular testing with a broad test menu and established lab network
  • Sector tailwinds: increased demand for cancer screening/diagnostics and potential incremental demand for CRO/CDMO services following positive biologics/mRNA oncology readthroughs
  • Recurring revenue model from high-volume test throughput and mix of clinical and pharma services provides revenue stability and visibility
  • Operational scale enables competitive pricing and faster commercialization of new assays and companion diagnostics
  • Macro backdrop of cautious risk-on tone and expectations of rate stability supports equity appetite for growth-oriented healthcare names in the near term

Risks

  • Reimbursement and payer pressure driven by payers' strategic rationalization and focus on cost control could compress pricing and margins
  • Intense competition from other specialty labs and diagnostics firms (including large integrated diagnostics players and emerging liquid biopsy firms) could pressure volumes and pricing
  • Volume volatility tied to screening adoption rates, referral patterns, and potential delays in new test uptake
  • Execution risk on capacity expansion, integration of any acquisitions, and sustaining margins while investing in automation/AI
  • Regulatory and compliance risks specific to laboratory testing and any changes in coverage policies for oncology diagnostics
  • Macroeconomic or geopolitical shocks that reduce elective testing or slow institutional flows into growth healthcare names

See today's live rating, score and targets

Members see the live hourly rating for NEO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.